Skip to main
HCA
HCA logo

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare (HCA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 41%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

HCA Healthcare reported impressive financial metrics in its 3Q25 results, including a same-facility revenue increase of 9.2% and a year-over-year increase of 7.1% in inpatient revenue per admission, indicating strong demand for its services. The company's management raised its 2025 adjusted EBITDA guidance to a range of $15.25 billion to $15.65 billion, driven significantly by core operational outperformance. The growth in Medicare Advantage volumes by 4.8% year-over-year, alongside a favorable payer mix contributing to higher admission pricing, further highlights HCA's operational strength and resilience in a competitive market.

Bears say

HCA Healthcare's total debt to last twelve months (LTM) EBITDA ratio decreased to 2.9x in the third quarter of 2025, indicating a potential easing of its leverage concerns; however, prolonged pressure on earnings growth and valuation remains evident. The company's anticipated 5% headwind to earnings estimates and subsequent multiple contraction to an 8.75x valuation underline a cautious outlook for future profitability. Additionally, despite slight improvements in supply expenses, the growth estimate for 2026 at $16.052 billion reflects a suboptimal trajectory, positioning it below the company's long-term growth expectations amidst broader economic uncertainties.

HCA Healthcare (HCA) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 41% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HCA Healthcare (HCA) Forecast

Analysts have given HCA Healthcare (HCA) a Buy based on their latest research and market trends.

According to 17 analysts, HCA Healthcare (HCA) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $472.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $472.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HCA Healthcare (HCA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.